Journal of Clinical Oncology
Articles in this Issue
PANOVA-3: Phase 3 study of tumor treating fields (TTFields) with gemcitabine and nab-paclitaxel for locally advanced pancreatic ductal adenocarcinoma (LA-PAC).
LBA4005 Background: To date, no phase 3 clinical trial has demonstrated an overall survival (OS) benefit in patients with locally advanced pancreatic aden...
Results of a randomized phase III trial of pre-operative chemotherapy with mFOLFIRINOX or PAXG regimen for stage I-III pancreatic ductal adenocarcinoma.
LBA4004 Background: Preoperative mFOLFIRINOX is a treatment option for patients (pts) with resectable/borderline resectable (R/BR) pancreatic ductal adeno...
NRG-BR003: A randomized phase III trial comparing doxorubicin plus cyclophosphamide followed by weekly paclitaxel with or without carboplatin for node-positive or high-risk node-negative TNBC.
LBA509 Background: NRG-BR003 is a phase III, randomized trial evaluating whether the addition of carboplatin (carbo) to an...
First-line encorafenib + cetuximab + mFOLFOX6 in BRAF V600E-mutant metastatic colorectal cancer (BREAKWATER): Progression-free survival and updated overall survival analyses.
LBA3500 Background: BREAKWATER (NCT04607421) is an open-label, global, randomized, phase 3 study evaluating first-line (1L) encorafenib + cetuximab (EC) ±...
Anesthesia type during surgery for treatment of biologically aggressive cancers: Results of the GA-CARES randomized, multicenter trial.
LBA1512 Background: Surgical resection is a widely used treatment for cancer. Patients can be “seeded” with their own cancer cells during surgery, with th...
Mitomycin plus BCG as adjuvant intravesical therapy for high-risk, non–muscle-invasive bladder cancer: A randomized phase 3 trial (ANZUP 1301).
LBA4504 Background: Intravesical BCG is the standard of care for high-risk non-muscle invasive bladder (NMIBC) after maximal transurethral resection. Avai...
Phase 3 AMPLITUDE trial: Niraparib (NIRA) and abiraterone acetate plus prednisone (AAP) for metastatic castration-sensitive prostate cancer (mCSPC) patients (pts) with alterations in homologous recombination repair (HRR) genes.
LBA5006 Background: NIRA is a highly selective and potent inhibitor of poly (ADP-ribose) polymerase (PARP)-1/2. In the MAGNITUDE trial, NIRA + AAP signifi...